



Koronis Pharmaceuticals to Present at 2010 BIO International Convention

Seattle, WA (April 29, 2010) – Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that it will present at the 2010 BIO International Convention, being held May 3-6 at McCormick Place, Chicago, IL. Jean-Pierre Laurent, Ph.D., Koronis COO, will present clinical data demonstrating proof-of-concept of Koronis' lead HIV therapeutic, KP-1461. Dr. Laurent's presentation will occur as part of the BIO Business Forum on Wednesday, May 5, at 10:45am CT, Room C.

“The data indicate significant drug activity of KP-1461 in HIV-infected subjects in the manner predicted by the Viral Decay Acceleration™ mechanism of action,” stated Dr. Laurent. “This drug activity, combined with a well-tolerated safety profile, and no evidence that KP-1461 increases resistance to standard antiretroviral drugs, provide strong support for continued development of KP-1461.”

Koronis is currently working with Rondaxe, a drug development services company (www.rondaxe.com), to secure strategic partnerships to advance KP-1461 through the next phases of development.

About Koronis

[Koronis Pharmaceuticals, Inc.](http://www.koronispharma.com) is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, [Viral Decay Acceleration™](#) (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV). The Company also has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit www.koronispharma.com.

###

Media Contact:

Julie Rathbun
Rathbun Communications, Inc.
julie@rathbuncomm.com
Tel : (206) 769-9219